Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States | Zendy

Adi EldarLissai | Zendy; Joshua T. Cohen | Zendy; Samantha MeltzerBrody | Zendy; Margaret E. Gerbasi | Zendy; Elizabeth Chertavian | Zendy; Paul Hodgkins | Zendy; Julia C. Bond | Zendy; Scott J. Johnson | Zendy

Open Access

Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States

Author(s) -

Adi EldarLissai,

Joshua T. Cohen,

Samantha MeltzerBrody,

Margaret E. Gerbasi,

Elizabeth Chertavian,

Paul Hodgkins,

Julia C. Bond,

Scott J. Johnson

Publication year - 2020

Publication title -

journal of managed care and specialty pharmacy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.126

H-Index - 63

eISSN - 2376-1032

pISSN - 2376-0540

DOI - 10.18553/jmcp.2020.19306

Subject(s) - medicine , depression (economics) , cost effectiveness , population , pediatrics , risk analysis (engineering) , environmental health , economics , macroeconomics

Brexanolone injection (BRX) was approved by the FDA in 2019 for the treatment of adult patients with postpartum depression (PPD), but its cost-effectiveness has not yet been evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog